Board approves 51% stake acquisition in Matrix Labs via share swap

Fund Raising View source PDF Explain this filing

ONEGLOBAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.9%Reaction day

₹527.15

prior close

₹547.80

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%+2.3% vs market

Healthcare Service Provider peers, median of 28sector-0.4%+3.3% vs sector

On the reaction day the stock moved 2.3 pts more than Nifty Microcap 250 and 3.3 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.0

15m

-0.1

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.9+0.7+2.3-0.4+3.3

Next day

-0.4+1.1-1.5-0.5+0.1

+0.9+1.6-0.7-0.4+1.3

+2.6+1.5+1.2-0.7+3.3

+3.4+1.3+2.1-1.1+4.5

+2.8+1.4+1.4-1.0+3.8

-1.1-2.1+1.0-1.8+0.7

15d

+3.6-0.9+4.5-3.3+6.8

+4.1-1.4+5.5-5.7+9.8

-16.5-5.5-11.0-6.6-9.9

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 28Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved acquiring 51% stake each in Matrix Labs Diagnocare (FY25 turnover Rs 171.30 Cr) and Matrix Labs Pvt Ltd (Rs 8.92 Cr) via share swap. Will allot 7,15,040 equity shares at Rs 553 each (total about Rs 39.54 Cr) to selling shareholders. Also increased authorised capital from Rs 25.05 Cr to Rs 50 Cr, reappointed statutory auditors and appointed new internal auditors. 34th AGM set for Sept 29, 2026.

Likely market impact

Diversifies into healthcare and diagnostics via share swap. Will dilute existing shareholders and make both targets subsidiaries pending approvals.